A First-in-Human Study of ZE66-0205 in Healthy Volunteers

This first-in-human study will evaluate ZE66-0205 in healthy adults. The main purpose is to assess the safety and tolerability of single oral doses and, if evaluated, two doses given on Day 1. The study will also assess how ZE66-0205 is absorbed, distributed, and eliminated from the body and how it affects MALT1 levels in blood cells. Participants will be assigned by chance to receive ZE66-0205 or placebo in sequential ascending-dose cohorts.

NCT Number	NCT07735728
Lead Sponsor	Eilean Therapeutics
Conditions	Healthy Volunteers (HV)
Enrollment	32 participants
Start Date	2026-08-15
Primary Completion	2027-08-15 (estimated)
Study Completion	2027-08-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-14